Eli Lilly and Company Stock News

Eli Lilly has plenty of medium-term catalysts that should power a strong performance through 2030. Berkshire Hathaway, by contrast, is facing some headwinds that may limit its upside.

Eli Lilly struck a deal with President Donald Trump, lowering the prices of its blockbuster weight loss drugs. In return, Lilly gains exemption from import tariffs and other benefits.

President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs.  Medicare will start covering GLP-1s for obesity for certain patients for the first time beginning in mid-2026 – a shift that some experts say will open access to millions of older adults and could spur more employers and other private...

Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but the new deal could boost long-term revenue by increasing drug accessibility and wiping out compounded competition. Despite price cuts, LLY's strong US manufacturing presence and blockbuster tirzepa...

Eli Lilly stock is nearing a buy point and a high. The White House signed a historic deal to slash obesity drug prices.

Eli Lilly's blockbuster obesity drug Mounjaro became India's top-selling drug by value for the month of October with sales hitting 1 billion rupees ($11.38 million), research firm Pharmarack said on Friday.

Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.

INDIANAPOLIS , Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D.